Pulsfeldablationsindexmetrik zur Läsionsbeurteilung
Anmelder: St. Jude Medical, Cardiology Division, Inc. 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4752898
- Anmeldetag
- 28. November 2025
- Veröffentlichung
- 3. Juni 2026
- Rechtsraum
- EP
- IPC
- G16H20/40, A61B18/14
Abstract
A method of assessing lesion formation associated with pulsed field ablation (PFA) therapy delivered to a selected location by a PFA catheter includes measuring pre-therapy impedance using one or more electrodes located on the catheter and delivering a first PFA application. An intra-therapy/post-therapy impedance is measured using the one or more electrodes located on the catheter and a PFA index (PI) metric is calculated based on a model that combines the measured pre-therapy impedance, the measured intra-therapy/post-therapy impedance, and attributes of the first PFA application delivered, wherein the PI metric is representative of a likelihood that the lesion has reached a selected size.
Anmelder
- Firma
- St. Jude Medical, Cardiology Division, Inc.
- Land
- 🇺🇸 USA
St. Jude Medical, Cardiology Division, Inc. ist eine US-amerikanische Konzerneinheit für kardiologische Medizinprodukte (heute Teil von Abbott) mit Patenten zu Herzkathetern und Kardiologie-Implantaten.
1.240 Patente in unserer Datenbank
Vertreten von
-
Mathys & Squire
Mathys & Squire · München